1. Canagliflozin: Real World Experience

2. Buysman EK, et al. BMC Endocr Disord. 2015 Nov 2;15(1):67.

3. Methods
Retrospective cohort study of data obtained from a large health plan database
The data of adult T2DM patients (≥18 years) taking Canagliflozin between April and October 2013 were included
Changes in glycemic control were evaluated, along with characteristics of enrolled patients & changes in treatment patterns
Buysman EK, et al. BMC Endocr Disord Nov 2;15(1):67.

4. Canagliflozin usage with respect to other Antihyperglycemic Agent (AHA)
20% patients taking Cana monotherapy
50% patients taking Cana with 2 or more other AHA
30% patients taking Cana as add on to 1 AHA
Buysman EK, et al. BMC Endocr Disord Nov 2;15(1):67.

5. From Clinical Trial to Clinical Practice: Higher the baseline HbA1c better the reduction with Cana
Buysman EK, et al. BMC Endocr Disord Nov 2;15(1):67.

6. From Clinical Trial to Clinical Practice: Higher the baseline HbA1c better the reduction with Cana
Greatest reduction in HbA1c in patients with the highest baseline HbA1c levels
Buysman EK, et al. BMC Endocr Disord Nov 2;15(1):67.

7. From Clinical Trial to Clinical Practice : AHA discontinuations after addition of Canagliflozin
20% patients appeared to discontinue at least one of the AHAs from their baseline regimen
A trend toward lower AHA use for metformin, SUs, insulin, DPP4i, GLP-1 agonists and thiazolidinediones, ranging from −11 % to −16 %
A high median adherence of 86% was seen with Canagliflozin*
*in patients with two or more canagliflozin fills

8. High Adherence with Canagliflozin: Possible reasons
Canagliflozin can help to increase motivation and self-esteem in patients with T2DM as in addition to good glycemic control it also offers clinical benefits i.e., body wt. reduction and lowering of BP
This can lead to greater motivation to conform to healthy behaviors including medication-taking
Such benefits can improve the overall effectiveness of therapy by creating a positive cycle of well-being that motivates patients to implement and sustain the necessary lifestyle changes that are an important feature of diabetes self- management
Buysman EK, et al. BMC Endocr Disord Nov 2;15(1):67.

9. Conclusion In this real-world setting, with Canagliflozin
Significant improvements in A1C were observed in the first 6 months of Canagliflozin usage
The results were consistent with those observed in the RCTs
A substantial proportion of patients were able to attain their A1C goals
A trend to lower other AHA use was observed, indicating Canagliflozin could potentially lead to cost offsets in treating T2DM
Buysman EK, et al. BMC Endocr Disord Nov 2;15(1):67.